Д-р Гоце Христов, специјалист по интерна медицина и супспецијалист дијабетолог денеска е именуван за нов директор на ЈЗУ Општа Болница – Струмица. Тој ќе ја замени досегашната директорка д-р Катерина Кузмановска, која оваа функција ја извршуваше од јануари 2021 година.
Д-р Гоце Христов кој во ЈЗУ Општа Болница – Струмица работи од 2012 година, средното образование го завршил во СОУ „Јане Сандански“ во Струмица, а високото образование на Универзитетот „Св. Кирил и Методиј“ во Скопје на Факултетот за медицина.
Специјализира Интерни болести на Универзитет „Св. Кирил и Методиј“ – Факултет за медицина, а на истиот факултет и Супспецијализација: Дијабетологија.
Од 1 декември 2022 година е на Докторски студии на Универзитетот „Гоце Делчев“ во Штип. Д-р Христов е едукатор на Универзитетот „Гоце Делчев“ – Кампус Струмица.
Едукативни курсеви:
01.08.2006-01.09.2006-completing a professional exchange programme according to the regulations of the Standing Committee on Professional Exchange of International Federation of Medical Students’ Associations at the department of Cardiology in the Hospital N 2 Szczecin-Poland,under the supervision of Prof.Dr.Hab.Zdzislawa Kornacewicz-Jach.
01.12.2008-01.12.2011 – Volunteer at University Clinic of Pulmology and Alergology, Skopje
02.11.2015-02.01.2016- compleating a training course in the Digestive Endoscopy Unit, Catholic University, Roma for all Upper and Lower GI cases in Universita Catolica del Sacro Cuore, Facolta di Medicine e Chirurgia Agostino Gemelli Rome.
01.12.2015-02.12.2015- Cook Medical Basic ERCP Training Programme at the Europian Endoscopy Training Centre, Rome.
01.03.2018-01.06.2018 – Completing a course of ultrasonography of thyroid gland at University Clinic of Endocrinology, Diabetes and Metabolic diseases, Skopje.
01.06.2023-06.06.2023- attending the Digestive Endoscopy Unit , Gemelli Hospital-Rome, for observation of all the cases carried in the Unit.
23.10.2023-27.10.2023- Completing a course of color doppler ulrasonography of neck vessels at Policlinic “Antamedica”, Belgrade.
30.10.2023-03.11.2023- Completing a course of peripheral vascular color doppler ulrasonography at Policlinic “Antamedica”, Belgrade.
Автор/коавтор на научна работа
SGLT-2 Inhibitors and GLP-1 RA may prevent cardiovascular and chronic kidney disease progression in patients regardless the diabetic status, 2022- BANTAO Journal 2021; 19(2):65-66,
-Association of FGF23 with micro and macrovascular complications and bone mineral metabolism in patients with DMT2 in the early stage of CKD: a pilot study, BANTAO Journal 2022; 20(1):6-12,
-Egzacerbation of COPD, 2022
-Is it Asthma, or something else, 2022
-Editing brochure: Care for body weight in patient with T2DM, 2022
Editing brochure: Care for foot in patient with T2DM, 2022
-PREVENAR 13- “The benefits of the pneumococcal vaccine in the adult population”,2023
-Oral semaglutide – A cariometabolic Approach to dealing with T2DM, 2023
-Mistakes in the management of asthma control, 2023
-Diagnostic dilemmas between asthma and COPD, 2023
-Remarkable blood glycemic and body weight efficacy of oral semaglutide (Rybelsus) in a short period, 2023 ( 8th Diabetes days in Macedonia with international participation)
-Once-weekly semaglutide use in glucagon-like peptide-1 receptor agonist naïve patients with type 2 diabetes in North Macedonia: Real-world data from the MIRAGE study, Journals Elsevier-Diabetes Research and Clinical Practice (https://doi.org/10.1016/j.diabres.2023.111018), 2023.
-A New Hope on the Horizon for Kidney and Cardiovascular Protection with SGLT2 Inhibitors, GLP-1 RA, and Mineralocorticoid Receptor Antagonists in Type 2 Diabetic and Chronic Kidney Disease Patients. Metab Syndr Relat Disord. 2024 Apr;22(3):170-178.doi: 10,1089/met.2023.0227. Epub 2024 Feb 21. PMID: 38386800.
Член на научни медицински едукации
-Scientific association of endocrinologist and diabetologists of Macedonia
-Macedonian respiratory society.
-Scientific association of obesity of Macedonia
Истражувач во клинички студии
-International study for research on the management of arterial hypertension and hypercholesterolemia in renal clinical conditions .
-Open prospective multicenter observational study to determine the efficacy, tolerability and safety of Vildagliptin (Agnis) in patients with type 2 diabetes mellitus,2022.
-Clinical study EMEA/H/C/004174_OZEMPIC_V01 , 2022
-Clinical Trial: A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER).
-Clinical Trial: A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma. (EXHALE-2).
